Evaluation of Exacerbation Severity in Patients with COPD Exacerbations According to the GOLD 2023 Report: Prospective, Multicenter, Real-Life Study

Résumé fourni par la source

Background: This study aimed to evaluate and compare the severity of exacerbations in patients hospitalized with COPD exacerbations [ECOPD] based on the new severity classification defined in the GOLD 2023 report. Methods: A prospective, cross-sectional, and observational study included a total of 513 ECOPD patients from nine university hospitals. Results: The mean age of the total patients was 68.9±8.8 years, with 83.4% being male. The distribution of exacerbation severity was as follows: mild [24.4%], moderate [50.8%], and severe [24.8%]. The rate of ICU admission [0.8%-4.2%-27.5%] and in-hospital mortality [1.6%-3.9%-9.2%] increased progressively from the mild to the severe exacerbation group [p<0.001; p=0.012, respectively]. The 6-month mortality rate was higher in the moderate [20.5%] and severe [21.4%] exacerbation groups compared to the mild exacerbation group [9.8%] [p=0.015] [Figure-1]. erj;66/suppl_69/PA353/F1 F1 F1 Factors affecting 180-day mortality included age, smoking pack-years, mMRC score, hypoxemia, elevated CRP, low HCT, low eosinophil, CCI, and experiencing moderate to severe exacerbations. Conclusions: Our study demonstrates that the new ECOPD severity classification is a distinctive and objective tool for predicting ICU admission and in-hospital mortality.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.